Lesson plan
HBL20016
HBL20016, also known as 5-methylthio-6-fluoro-N,N-dimethyltryptamine (5-MeS-6-F-DMT), is a non-selective serotonin receptor agonist and serotonergic psychedelic of the tryptamine family related to 5-MeO-DMT. It is the 6-fluoro derivative of 5-MeS-DMT and the 5-methylthio derivative of 6-fluoro-DMT. The drug acts as an agonist of the serotonin 5-HT 1A , 5-HT 2A , 5-HT 2B , and 5-HT 2C receptors. Its activational potencies ( ) are 645 nM for the serotonin 5-HT 1A receptor, 1.64 nM for the serotonin 5-HT 2A receptor, 3.42 nM for the serotonin 5-HT 2B receptor, and 8.37 nM for the serotonin 5-HT 2C receptor. HBL20016 produces the head-twitch response (HTR), a behavioral proxy of psychedelic effects, in rodents, and hence would be expected to be hallucinogenic in humans. The HTR induced by HBL20016 is comparable in magnitude to that occurring with psilocybin. HBL20016 has shown antiobsessional-like effects in rodents, for instance against obsessive self-grooming. The chemical synthesis of HBL20016 has been described. HBL20016 was first described in the scientific literature in December 2024. It was developed by Negev Labs and Parow Entheobiosciences. A related drug, HBL20017 (4-F-5-MeS-DMT), which is a non-hallucinogenic agent with an otherwise mostly similar pharmacological profile, is under investigation for the potential treatment of obsessive–compulsive disorder (OCD).
Article summary
HBL20016, also known as 5-methylthio-6-fluoro-N,N-dimethyltryptamine (5-MeS-6-F-DMT), is a non-selective serotonin receptor agonist and serotonergic psychedelic of the tryptamine family related to 5-MeO-DMT. It is the 6-fluoro derivative of 5-MeS-DMT and the 5-methylthio derivative of 6-fluoro-DMT. The drug acts as an agonist of the serotonin 5-HT 1A , 5-HT 2A , 5-HT 2B , and 5-HT 2C receptors. Its activational potencies ( ) are 645 nM for the serotonin 5-HT 1A receptor, 1.64 nM for the serotonin 5-HT 2A receptor, 3.42 nM for the serotonin 5-HT 2B receptor, and 8.37 nM for the serotonin 5-HT 2C receptor. HBL20016 produces the head-twitch response (HTR), a behavioral proxy of psychedelic effects, in rodents, and hence would be expected to be hallucinogenic in humans. The HTR induced by HBL20016 is comparable in magnitude to that occurring with psilocybin. HBL20016 has shown antiobsessional-like effects in rodents, for instance against obsessive self-grooming. The chemical synthesis of HBL20016 has been described. HBL20016 was first described in the scientific literature in December 2024. It was developed by Negev Labs and Parow Entheobiosciences. A related drug, HBL20017 (4-F-5-MeS-DMT), which is a non-hallucinogenic agent with an otherwise mostly similar pharmacological profile, is under investigation for the potential treatment of obsessive–compulsive disorder (OCD).
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.